LEXICON PHARMACEUTICALS, INC. Revenue from Contract with Customer, Including Assessed Tax
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Revenue from Contract with Customer, Including Assessed Tax of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-03.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2023-03-03
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-12-31 was $9.80M, a 66.02% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-09-30 was $446.00K, a 97.89% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-06-30 was $6.36M, a 21.53% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2017-12-31 was $28.84M.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for fiscal 2022 was $0.00.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for fiscal 2020 was $33.00K, a 99.99% decline from fiscal 2019.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for fiscal 2019 was $289.23M, a 697.42% increase from fiscal 2018.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-03 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-03 | |||
| 2020-12-31 | $33.00K 10-K · filed 2023-03-03 | |||
| 2019-12-31 | $289.23M 10-K · filed 2022-03-10 | |||
| 2018-12-31 | $9.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $10.25M derived: sum of 2 quarters · filed 2021-03-12 | $16.61M derived: sum of 3 quarters · filed 2021-03-12 | $36.27M 10-K · filed 2021-03-12 |
| 2018-09-30 | $446.00K 10-Q · filed 2018-11-01 | $6.80M derived: sum of 2 quarters · filed 2018-11-01 | $26.47M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $6.36M 10-Q · filed 2018-07-30 | $26.02M 10-Q · filed 2018-07-30 | ||
| 2017-12-31 | $28.84M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $49.95M derived: sum of 2 quarters · filed 2020-03-12 | $58.06M derived: sum of 3 quarters · filed 2020-03-12 | $75.62M 10-K · filed 2020-03-12 |
| 2017-09-30 | $21.11M 10-Q · filed 2018-11-01 | $29.22M derived: sum of 2 quarters · filed 2018-11-01 | $46.78M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $8.10M 10-Q · filed 2018-07-30 | $25.67M 10-Q · filed 2018-07-30 | ||
| 2016-12-31 | $79.10M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |